
Syndax Pharmaceuticals, Inc.: shareholders and insiders
Price
$8.56
November 18, 2026Market cap $755M
What Ploutos Investor adds for Syndax Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 35% since Nov 2, 2026, when the 10-Q these figures come from was filed ($13.10 then, $8.56 on Nov 18, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 12, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$2.9M
4 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan73%
- The rest27%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $2.9M by 4 people
- 2025: no buys, no sales
- 2026: no buys, sold $2.9M by 4 people
- Oct 29, 2026Dennis PodlesakDirectorKind10b5-1
- Oct 29, 2026Dennis PodlesakDirectorKind10b5-1
- Jul 8, 2026Michael A MetzgerChief Executive OfficerKind10b5-1
- Jul 8, 2026Michael A MetzgerChief Executive OfficerKind10b5-1
- Jun 12, 2026Nicholas A.J. BotwoodHead of R&D, CMOKind10b5-1
- Jun 12, 2026Nicholas A.J. BotwoodHead of R&D, CMOKind10b5-1
- Jun 11, 2026Nicholas A.J. BotwoodHead of R&D, CMOKind10b5-1
- Jun 11, 2026Nicholas A.J. BotwoodHead of R&D, CMOKind10b5-1
- Jun 1, 2026Keith A. GoldanChief Financial OfficerKind
- Jun 1, 2026Michael A MetzgerChief Executive OfficerKind
- Feb 9, 2026Keith A. GoldanChief Financial OfficerKind
- Feb 9, 2026Michael A MetzgerChief Executive OfficerKind
- Feb 6, 2026Keith A. GoldanChief Financial OfficerKind
- Feb 6, 2026Michael A MetzgerChief Executive OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | Dennis PodlesakDirector | 10b5-1 | 8,000 | $11.81 | $94.5K | Form 4 |
| Oct 29, 2026 | Dennis PodlesakDirector | 10b5-1 | 8,000 | $14.21 | $113.7K | Form 4 |
| Jul 8, 2026 | Michael A MetzgerChief Executive Officer | 10b5-1 | 32.4K | $6.38 | $206.6K | Form 4 |
| Jul 8, 2026 | Michael A MetzgerChief Executive Officer | 10b5-1 | 32.4K | $24.24 | $784.8K | Form 4 |
| Jun 12, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | 10b5-1 | 31.2K | $13.82 | $431.7K | Form 4 |
| Jun 12, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | 10b5-1 | 31.2K | $18.14 | $566.6K | Form 4 |
| Jun 11, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | 10b5-1 | 22.5K | $13.82 | $311.2K | Form 4 |
| Jun 11, 2026 | Nicholas A.J. BotwoodHead of R&D, CMO | 10b5-1 | 34.3K | $18.00 | $617.0K | Form 4 |
| Jun 1, 2026 | Keith A. GoldanChief Financial Officer | 1,177 | $18.99 | $22.4K | Form 4 | |
| Jun 1, 2026 | Michael A MetzgerChief Executive Officer | 6,847 | $18.99 | $130.0K | Form 4 | |
| Feb 9, 2026 | Keith A. GoldanChief Financial Officer | 3,410 | $21.03 | $71.7K | Form 4 | |
| Feb 9, 2026 | Michael A MetzgerChief Executive Officer | 17.2K | $21.03 | $360.9K | Form 4 | |
| Feb 6, 2026 | Keith A. GoldanChief Financial Officer | 2,082 | $20.62 | $42.9K | Form 4 | |
| Feb 6, 2026 | Michael A MetzgerChief Executive Officer | 7,412 | $20.62 | $152.8K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 2, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by SNDX's officers and directors from 2016 up to November 18, 2025, 10 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 5 more, back to 2016
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Kynam Capital Management, LPwith 2 more personsShare of class9.98%
- BlackRock, Inc.Share of class7.80%
- The Goldman Sachs Groupwith 1 more personShare of class6.50%
- State StreetShare of class5.20%
- Vanguard Capital ManagementShare of class5.05%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Kynam Capital Management, LPwith 2 more persons | 9.98% | 8.52M | Feb 14, 2025 | 13G/A | |
| BlackRock, Inc. | 7.80% | 6.74M | Apr 17, 2025 | 13G/A | |
| The Goldman Sachs Groupwith 1 more person | 6.50% | 5.58M | Aug 13, 20253 filings since Feb 12, 2025 | 13G/A | |
| State Street | 5.20% | 4.65M | Nov 10, 20263 filings since Feb 9, 2026 | 13G | |
| Vanguard Capital Management | 5.05% | 4.46M | Apr 30, 2026 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter-41%
- D.E. ShawIn the quarter-58%
- AQR CapitalIn the quarter+34%
- Citadel Advisors (Griffin)In the quarter-21%
- Renaissance TechnologiesIn the quarter-40%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 1.22M | -41% | $23M | 0.02% |
| D.E. Shaw | 520.9K | -58% | $9.8M | 0.01% |
| AQR Capital | 1.14M | +34% | $22M | 0.01% |
| Citadel Advisors (Griffin) | 204.5K | -21% | $3.8M | 0.00% |
| Renaissance Technologies | 192.1K | -40% | $3.6M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 20.4% of its shares outstanding were held short, -1.3% since the report before.
- Shares held short
- 18.00M
- 20.4%
- Since the report before18.23M on Sep 30, 2026
- -1.3%
- 7.6
- 2.36M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 82%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.98M
- Nov 15, 2023: Shares held short 10.62M
- Nov 30, 2023: Shares held short 10.23M
- Dec 15, 2023: Shares held short 10.34M
- Dec 29, 2023: Shares held short 8.38M
- Jan 12, 2024: Shares held short 8.69M
- Jan 31, 2024: Shares held short 8.69M
- Feb 15, 2024: Shares held short 8.60M
- Feb 29, 2024: Shares held short 9.09M
- Mar 15, 2024: Shares held short 8.33M
- Mar 28, 2024: Shares held short 9.62M
- Apr 15, 2024: Shares held short 9.60M
- Apr 30, 2024: Shares held short 10.11M
- May 15, 2024: Shares held short 10.03M
- May 31, 2024: Shares held short 9.65M
- Jun 14, 2024: Shares held short 9.92M
- Jun 28, 2024: Shares held short 8.34M
- Jul 15, 2024: Shares held short 8.52M
- Jul 31, 2024: Shares held short 8.59M
- Aug 15, 2024: Shares held short 9.43M
- Aug 30, 2024: Shares held short 9.49M
- Sep 13, 2024: Shares held short 9.67M
- Sep 30, 2024: Shares held short 10.08M
- Oct 15, 2024: Shares held short 10.51M
- Oct 31, 2024: Shares held short 10.66M
- Nov 15, 2024: Shares held short 10.60M
- Nov 29, 2024: Shares held short 14.40M
- Dec 13, 2024: Shares held short 16.36M
- Dec 31, 2024: Shares held short 21.31M
- Jan 15, 2025: Shares held short 22.38M
- Jan 31, 2025: Shares held short 22.20M
- Feb 14, 2025: Shares held short 21.55M
- Feb 28, 2025: Shares held short 19.20M
- Mar 14, 2025: Shares held short 18.82M
- Mar 31, 2025: Shares held short 19.36M
- Apr 15, 2025: Shares held short 21.17M
- Apr 30, 2025: Shares held short 21.66M
- May 15, 2025: Shares held short 21.73M
- May 30, 2025: Shares held short 23.14M
- Jun 13, 2025: Shares held short 22.00M
- Jun 30, 2025: Shares held short 23.87M
- Jul 15, 2025: Shares held short 23.69M
- Jul 31, 2025: Shares held short 23.90M
- Aug 15, 2025: Shares held short 20.61M
- Aug 29, 2025: Shares held short 20.92M
- Sep 15, 2025: Shares held short 23.14M
- Sep 30, 2025: Shares held short 22.81M
- Oct 15, 2025: Shares held short 22.02M
- Oct 31, 2025: Shares held short 25.34M
- Nov 14, 2025: Shares held short 25.62M
- Nov 28, 2025: Shares held short 25.22M
- Dec 15, 2025: Shares held short 22.83M
- Dec 31, 2025: Shares held short 22.57M
- Jan 15, 2026: Shares held short 22.34M
- Jan 30, 2026: Shares held short 21.15M
- Feb 13, 2026: Shares held short 22.12M
- Feb 27, 2026: Shares held short 21.80M
- Mar 13, 2026: Shares held short 20.49M
- Mar 31, 2026: Shares held short 20.70M
- Apr 15, 2026: Shares held short 20.97M
- Apr 30, 2026: Shares held short 19.91M
- May 15, 2026: Shares held short 21.71M
- May 29, 2026: Shares held short 16.64M
- Jun 15, 2026: Shares held short 19.86M
- Jun 30, 2026: Shares held short 21.81M
- Jul 15, 2026: Shares held short 20.82M
- Jul 31, 2026: Shares held short 22.67M
- Aug 14, 2026: Shares held short 22.90M
- Aug 31, 2026: Shares held short 21.68M
- Sep 15, 2026: Shares held short 20.66M
- Sep 30, 2026: Shares held short 18.23M
- Oct 15, 2026: Shares held short 18.00M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading32.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 32.4% of the shares in the reported trades were short sales, against 59.8% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 32.4%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 59.8%
- Change
- -27.4 pts
- Short sales a dayon average, of 1.65M shares
- 533.9K
- More than atof 3,656 US-listed companies, same days
- 7%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 44.1%
- Oct 13, 2026: Short sales 57.7%
- Oct 14, 2026: Short sales 61.3%
- Oct 15, 2026: Short sales 60.1%
- Oct 16, 2026: Short sales 48.3%
- Oct 19, 2026: Short sales 66%
- Oct 20, 2026: Short sales 37.5%
- Oct 21, 2026: Short sales 43.2%
- Oct 22, 2026: Short sales 31.5%
- Oct 23, 2026: Short sales 90.3%
- Oct 26, 2026: Short sales 45.6%
- Oct 27, 2026: Short sales 15.3%
- Oct 28, 2026: Short sales 44.5%
- Oct 29, 2026: Short sales 80.1%
- Oct 30, 2026: Short sales 40.6%
- Nov 2, 2026: Short sales 48.4%
- Nov 3, 2026: Short sales 41.4%
- Nov 4, 2026: Short sales 19.7%
- Nov 5, 2026: Short sales 29.5%
- Nov 6, 2026: Short sales 25.6%
- Nov 9, 2026: Short sales 49.2%
- Nov 10, 2026: Short sales 49.5%
- Nov 11, 2026: Short sales 18.9%
- Nov 12, 2026: Short sales 38.9%
- Nov 13, 2026: Short sales 59.7%
- Nov 16, 2026: Short sales 26.8%
- Nov 17, 2026: Short sales 30.9%
- Nov 18, 2026: Short sales 37.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Michael A MetzgerChief Executive OfficerDirectly484.8K
- Dennis PodlesakDirectorDirectly239.8K
- Keith A. GoldanChief Financial OfficerDirectly139.3K
- Keith KatkinDirectorDirectly100.0K
- Neil GallagherPresident, Head of R&DDirectly85.1K
- Martin H. Huber Jr.DirectorDirectly79.0K
- Nicholas A.J. BotwoodHead of R&D, CMODirectly60.9K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Michael A MetzgerChief Executive Officer | 484.8K | – | Jul 8, 2026 | Form 4 |
| Dennis PodlesakDirector | 239.8K | – | Oct 29, 2026 | Form 4 |
| Keith A. GoldanChief Financial Officer | 139.3K | – | Jun 1, 2026 | Form 4 |
| Keith KatkinDirector | 100.0K | – | May 19, 2025 | Form 4 |
| Neil GallagherPresident, Head of R&D | 85.1K | – | Feb 10, 2025 | Form 4 |
| Martin H. Huber Jr.Director | 79.0K | – | May 19, 2025 | Form 4 |
| Nicholas A.J. BotwoodHead of R&D, CMO | 60.9K | – | Jun 12, 2026 | Form 4 |
A lower bound: it counts only the 7 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.72%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.46%
- IBBiShares Biotechnology ETFWeight in the fund0.14%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.12%
- IWMiShares Russell 2000 ETFWeight in the fund0.06%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.05%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.04%
- VXFVanguard Extended Market Index FundWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.01%
14 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 229
- Q4 2025: Managers 231
- Q1 2026: Managers 249
- Q2 2026: Managers 242
Institutional investors by quarter
The fund managers holding SNDX, quarter by quarter, from Q1 2016 to Q2 2025, 38 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 242 managers held 108M shares, worth $2.4B. During the quarter 37 opened a position, 44 closed one, 93 added and 74 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+9.3%
- Kynam Capital ManagementIn the quarter
- Goldman Sachs GroupIn the quarter+17%
- State StreetIn the quarter+28%
- Bank of AmericaIn the quarter-4.8%
- Vanguard Capital ManagementIn the quarter+2.8%
- Deerfield ManagementIn the quarter
- Eversept PartnersIn the quarter-3.0%
- Geode Capital ManagementIn the quarter+20%
- Hood River Capital ManagementIn the quarter+8.9%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 9.02M | +9.3% | $197M |
| Kynam Capital Management | 8.05M | $176M | |
| Goldman Sachs Group | 5.86M | +17% | $128M |
| State Street | 5.66M | +28% | $124M |
| Bank of America | 4.05M | -4.8% | $88M |
| Vanguard Capital Management | 3.93M | +2.8% | $86M |
| Deerfield Management | 3.78M | $83M | |
| Eversept Partners | 2.80M | -3.0% | $61M |
| Geode Capital Management | 2.58M | +20% | $56M |
| Hood River Capital Management | 2.56M | +8.9% | $56M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Syndax Pharmaceuticals's filings show?
Who buys and sells is one part of Syndax Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have SNDX's insiders bought or sold?
From Jun 2, 2026 to Nov 12, 2026 Syndax Pharmaceuticals's insiders bought 0 and sold $2.2M of shares on the market. 93% of the sales were under set 10b5-1 plans.
Which well-known managers hold SNDX?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $23M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.